200 related articles for article (PubMed ID: 28270924)
1. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.
Beddhu S; Filipowicz R; Wang B; Wei G; Chen X; Roy AC; DuVall SL; Farrukh H; Habib AN; Bjordahl T; Simmons DL; Munger M; Stoddard G; Kohan DE; Greene T; Huang Y
Can J Kidney Health Dis; 2016; 3():2054358116675343. PubMed ID: 28270924
[TBL] [Abstract][Full Text] [Related]
2. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
5. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
7. Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia.
Gohda T; Yanagisawa N; Murakoshi M; Ueda S; Nishizaki Y; Nojiri S; Ohashi Y; Ohno I; Shibagaki Y; Imai N; Iimuro S; Kuwabara M; Hayakawa H; Kimura K; Hosoya T; Suzuki Y
Front Med (Lausanne); 2021; 8():634932. PubMed ID: 34322499
[No Abstract] [Full Text] [Related]
8. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
9. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
10. Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
Nata N; Ninwisut N; Inkong P; Supasyndh O; Satirapoj B
Sci Rep; 2023 Aug; 13(1):13494. PubMed ID: 37596359
[TBL] [Abstract][Full Text] [Related]
11. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
12. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
13. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
Kato S; Ando M; Mizukoshi T; Nagata T; Katsuno T; Kosugi T; Tsuboi N; Maruyama S
Nagoya J Med Sci; 2016 May; 78(2):135-42. PubMed ID: 27303100
[TBL] [Abstract][Full Text] [Related]
14. Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial.
Perrenoud L; Kruse NT; Andrews E; You Z; Chonchol M; Wu C; Ten Eyck P; Zepeda-Orozco D; Jalal D
Kidney Med; 2020; 2(2):155-161. PubMed ID: 32964203
[TBL] [Abstract][Full Text] [Related]
15. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
17. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.
Mukri MNA; Kong WY; Mustafar R; Shaharir SS; Shah SA; Abdul Gafor AH; Mohd R; Abdul Cader R; Kamaruzaman L
EXCLI J; 2018; 17():563-575. PubMed ID: 30108461
[No Abstract] [Full Text] [Related]
18. Evaluation the effectiveness of the Jiangniaosuan formulation in the treatment of hyperuricemic nephropathy in patients with chronic kidney disease stages 3-4: Study protocol of a randomized controlled trial.
Lu L; Xu L; He Y; Shen J; Xin J; Zhou J; Wang C; Wang Y; Pan X; Gao J
Contemp Clin Trials Commun; 2023 Apr; 32():101065. PubMed ID: 36793790
[TBL] [Abstract][Full Text] [Related]
19. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
20. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]